Diplomat Pharmacy celebrates four decades
FLINT, Mich. – Diplomat Pharmacy is celebrating 40 years of providing quality pharmacy services to its patients nationwide, the company announced Friday.
Diplomat, founded in 1975 by Dale Hagerman and son Phil Hagerman, its current chairman and CEO, has grown into the nation’s largest independent specialty pharmacy. Founded on the philosophy “take good care of patients, and the rest falls into place,” Diplomat is committed to helping patients with complex chronic conditions.
Today, Diplomat relies on its history of innovation to set the standard for patient care. What started as a small, regional operation has since led to a national enterprise focused on customized solutions for each patient’s individual needs. At the root of the company’s expansion is the desire to help more patients find health. “We remain committed to our philosophy by taking care of one patient at a time for happier lives and health that lasts,” Phil Hagerman said.
“Our patients are more than customers; they are remarkable stories of human triumph. It is our honor to support their health, helping them thrive in their lives,” Hagerman added. “Our philosophy continues to be as it was when my dad had the pharmacy almost 40 years ago and we look forward to upholding for the next 40 years to come.”
Test that identifies Strep A within eight minutes cleared by FDA
WALTHAM, Mass. – Alere on Thursday announced that its Alere i Strep A test has received marketing clearance from the Food and Drug Administration. Alere i Strep A is the first molecular test that detects Group A Streptococcus (GAS) bacteria in throat swab specimens in 8 minutes or less.
Upon receipt of this clearance from the FDA, Alere submitted an application for CLIA (Clinical Laboratory Improvement Amendments) waiver of the Alere i Strep A test. Other assays currently in development on the Alere i platform include respiratory syncytial virus (RSV), C. difficile and Chlamydia/Gonorrhoea.
"This FDA clearance brings the power of our Alere i molecular platform to the detection of Strep A," stated Avi Pelossof, global president infectious diseases at Alere. "The speed and accuracy of the Alere i Strep A test empower healthcare professionals to initiate the right treatment in an actionable timeframe, which is a critical step in reducing unnecessary prescription of antibiotics and enhancing operational efficiency."
The Alere i molecular platform was initially cleared for marketing by the FDA for the detection and differentiation of influenza A and B virus in June 2014. In January 2015, Alere i Influenza A & B became the first-ever molecular test to receive CLIA waiver, which allows for broad use by healthcare providers, ranging from hospitals and physician offices to clinics and other healthcare settings. Expanding the menu on the Alere i platform to include Strep A and potentially other assays increases the utility of the platform for a wider range of users. Furthermore, given the less seasonal nature of Strep A, its addition enhances the value of the platform for users on a year-round basis.
With BioRx deal closed, Diplomat becomes one of nation’s largest specialty infusion providers
FLINT, Mich. – Diplomat Pharmacy announced Wednesday it has completed the acquisition of BioRx, a highly specialized pharmacy and infusion services company that provides treatments for patients with ultra-orphan and rare, chronic diseases. With the close of this acquisition, the combined resources and capabilities will make Diplomat one of the nation's largest specialty infusion providers.
Diplomat and BioRx are dedicated to personalized medication therapies for patients with chronic and complex therapies. "The combined resources of both companies will better serve our patients with broader access to limited distribution drugs as Diplomat and BioRx manage a strong therapy mix," stated Phil Hagerman, Diplomat chairman and CEO. "The combination furthers our capabilities to roll out services to a larger national geographic footprint which will strengthen our ties with pharmaceutical manufactures by satisfying their demand for multi-channel reach."
"For payor partners, our expanded offering improves our ability to take care of patients regardless of benefits," said Phil Reilly, co-founder of BioRx.
Both BioRx co-founders, Rielly and Eric Hill, have made multi-year commitments to help lead the combined infusion services organization going forward.
Under the terms of the agreement, Diplomat is paying BioRx $210 million cash and approximately 4.05 million shares of Diplomat common stock. In 2014, BioRx generated approximately $227 million in revenue.
Loading Post Please Wait...